Compare Check Point Software Technologies Ltd (CHKP) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Check Point Software Technologies Ltd vs Incyte Corporation — how do they compare? Check Point Software Technologies Ltd trades at $129.5 (market cap $13.18B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Incyte Corporation is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, Check Point Software Technologies Ltd nearer its low. Which is the better fit depends on your goals.
| CHKP | INCY | |
|---|---|---|
Market Cap | $13.18B | $24.54B |
Sector | Technology | Health |
52-Week High | $206.91 | $129.93 |
52-Week Low | $112.47 | $81.61 |
Enterprise Value | $12.88B | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CHKP trades at $129.29, down 1.41% today, with a bearish technical signal as it hovers near support at $128. The stock shows strong fundamentals with a P/E of 13.24, net income margin of 37.93%, and consistent earnings beats in recent quarters. Recent news highlights AI security growth potential and insider selling activity.
The outlook is mixed: valuation appears attractive with a consensus price target of $146.92, but near-term risks include competitive pressures and margin declines. Upside depends on AI-driven revenue acceleration in 2027, while downside is capped by solid cash flow and profitability.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Check Point Software Technologies Ltd
Check Point is a global leader in cybersecurity solutions. It provides comprehensive protection against advanced cyber threats for corporate networks, cloud environments, mobile devices, and critical infrastructure.
Read more on CHKP →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
